42973-19-3

Upstream product

• 27727-37-3 benzyl p-hydroxyphenylacetate 
• 105-36-2 ethyl bromoacetate 
• 166954-03-6 benzyl 4-(2-tert-butoxy-2-oxoethoxy)phenylacetate 

Downstream Products

• 1408065-37-1 (S)-tert-butyl 6-(2-(4-(2-benzyloxy-2-oxoethyl)phenoxy)acetamido)-2-(N-isobutyl-4-methylphenylsulfonamido)hexanoate 
• 1408065-20-2 (S)-tert-butyl 6-(2-(4-(2-benzyloxy-2-oxoethyl)phenoxy)acetamido)-2-(N-isobutyl-4-methylphenylsulfonamido)hexanoate 

Relevant academic research and scientific papers

Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - Development of potential agents for the treatment of Alzheimer's disease

Systematic variation of membrane anchor, spacer and pharmacophore building blocks leads to an optimisation of the inhibitory effect of tripartite structures towards BACE1-induced cleavage of the amyloid precursor protein (APP). The Royal Society of Chemis